Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Subscribe To Our Newsletter & Stay Updated
